Clinical Trial Update: Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Daraxonrasib alone and in combination with gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Adenosquamous Carcinoma
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Daraxonrasib
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Status: RECRUITING